medigraphic.com
ISSN 1817-5996 (Electronic)

2013, Number 3

<< Back Next >>

Rev Cub de Reu 2013; 15 (3)

Muscular force and levels séricos of fosfocreatincinasa in patients with polimiositis and/or dermatomiositis

Arguelles ZAC, Infante AA, Casas FN, Pérez CD, Chico CA, Sánchez BY, Estévez TM

Language: Spanish
References: 26
Page: 131-138
PDF size: 211.74 Kb.


ABSTRACT

Introduction:Polymyositis is a conjunctive tissue disease that is characterized by the presence of proximal muscular weakness, the breathing muscles, myocardium and deglution muscles. When it is associated with skin manifestations it is denominated dermatomyositis.
Objective: To determine muscular force and serum phosphokreatincinase levels in patient with dermatomyositis / polymyositis suspicion.
Methodology: Descriptive, longitudinal and retrospective study. We were kept in mind the Bohman and cols criteria for the positive diagnosis. The age was described at the moment of the disease diagnosis as well as gender. Muscular force was evaluated according to the Medical Research Council scale. Phosphokreatincinase levels were carried out using an enzymatic test that determines the enzymatic activity in serum.
Results: The biggest age frequency at the diagnosis was the group understood between 42 and 52 years old with 26,3 %. The biggest gender frequency corresponded to the feminine with 84,2 %. The biggest frequency according to the range of phosphokreatincinase levels at the diagnosis corresponded to the group with concentration of 500,1 UI and more; with 73,7 %. The biggest frequency with regard to the muscular pelvic force evaluation according to the Medical Research Council scale corresponded to 3th grade with 57,9 %. The biggest frequency with regard to the muscular scapular force evaluation corresponded to the 3th grade with 56,1 %.
Conclusions: Serum phosphokreatincinase levels evaluation and the decrease of muscular pelvic and scapular force were important approaches for the dermatomyositis / polymyositis diagnosis in our patients.


REFERENCES

  1. Bohan A, Peter J. Polymyositis and Dermatomyositis (First of two parts). N Engl J Med. 1975;292:7:344-7.

  2. Bohan A, Peter J. Polymyositis and Dermatomyositis (Second of two parts). NEngl J Med. 1975;292:8:403-7.

  3. Restrepo JF. Dermatomiositis-polimiositis. Revista Colombiana de Reumatología. 2003;10(2):135-41.

  4. Wagner E. Ein Fall von akuterPolymyositis. Deutsch Arch klin Med. 1886;40:241-66.

  5. Unverricht H. Dermatomyositisacuta. Deutsch Med Wchnscher. 1891;17:41–4.

  6. Hofman J. Miopatías Inflamatorias Polimiositis – Dermatomiositis. Reumatología. 2005;21(3):112-5.

  7. Secretaría de Salud de México. Diagnóstico y tratamiento de Polimiositis y Dermatomiositis. México DF: Ed. Secretaría de Salud; 2011.

  8. Institutos Nacionales de Salud. Examen de creatina-fosfocinasa. New York: Ed. Biblioteca Nacional de Medicina; 2009.

  9. Vargas-Leguás H, Selva-O'Callaghan A, Campins-Martí M, Hermosilla Pérez E, Grau-Junyent JM, Martínez Gómez X, et al. Polymyositis-dermatomyositis: incidence in Spain (1997-2004). MedClin (Barc). 2007;129:721-4.

  10. Pinto LF, Ángel AM, Bohórquez AR, López CM. Caracterización de los pacientes con polimiositis y dermatomiositis del Servicio de Reumatología del Instituto de Seguros Sociales de Medellín, Colombia, 1992-2000. Revista Colombiana de Reumatología. 2003;10(1):9-18.

  11. Almanza Liranza Z, Fernández Couce G, Perea Corral J, Quintana Mirabal S, Gómez de Cadiz AT. Dermatomiositis: a propósito de 3 casosinteresantes. Rev CubanaPediatr. 2010;82(4):102-11.

  12. Hilton-Jones D. Observations on the classification of the inflammatory myopathies. Presse Med. 2011;40:199-208.

  13. Medical Research Council. Aids to the examination of the peripheral nervous system, Memorandum no. 45. London: Ed. HerMajesty'sStationery Office; 1981.

  14. Chávez González N, Sánchez Pérez Y, Elías Montes Y. Dermatomiositis. Presentación de un caso pediátrico. Multimed [revista en Internet] 2012 [citado 19 septiembre 2013]; 16(1):0-0. Disponible en: http://www.multimedgrm.sld.cu/Documentos%20pdf/Volumen16-1/13.pdf

  15. Irazoque-Palazuelos F, Barragán-Navarro Y. Epidemiología, etiología y clasificación. ReumatolClin. 2009;5 Supl.3:S2-5.

  16. Berrocal A, Ramirez E, Calvo A. El embarazo no exacerba la dermatomiositis. Rev Med Hered. 1999;10(3):125-8.

  17. Bernatsky S, Joseph L, Pineau CA, Bélisle P, Boivin JF, Banerjee D, et al. Estimating the prevalence of polymyositis and dermatomyositis from administrative data: age, sex and regional differences. Ann Rheum Dis. 2009;68(7):1192-6.

  18. Silva Fernández L, Barbadillo Mateos C, Fernández Castro M, Otón Sánchez T. Los otros biomarcadores. ¿Qué debe saber el reumatólogo? Semin Fund Esp Reumatol. 2011;212:0-6.

  19. Vidarte Orrego G, Álvarez Llanos E, Lozano Miranda Z. Dermatomiositis amiopática: reporte de un caso y revisión de la literatura. Dermatol Peru. 2008;18(1):45-50.

  20. Dimachkie MM. Idiophatic inflammatory myopathies., J Neuroimmunol. 2011;231:32-42.

  21. Amato AA, Barohn RJ. Evaluation and treatment of inflammatory myophaties. J NeurolNeurosurg Psychiatry. 2009;80:1060-8.

  22. Cordeiro AC, Isenberg DA. Treatment of inflammatory myophaties. Postgrad Med J. 2006;82:417-24.

  23. Safety and efficacy of exercise training in patients with an idiopathic inflammatory myopathy-a systematic review. Rheumatology (Oxford). 2011;50(11):2113-24.

  24. Vázquez del Mercado M, Arana V, Heron M. Alteraciones histológicas y moleculares en miopatías inflamatorias. ReumatolClin. 2009;5:20-2.

  25. Greenberg SA, Pinkus JL, Pinkus GS. Interferon-alpha / beta mediated innate immune mechanisms in dermatomyositis. Ann Neurol. 2005;57:664-78. Revista Cubana de Reumatología ISSN: 1817-5996 Volumen XV, Número 3; 2013: 131-138 138 Fuerza muscular y niveles séricos de fosfocreatincinasa en pacientes con polimiositis y/o dermatomiositis

  26. Mammen AL. Dermatomyositis and polymyositis Clinical presentation, autoantibodies and pathogenesis. Ann NY




2020     |     www.medigraphic.com